Form 8-K · Current Report · Filed 2025-02-21
Roivant Sciences Ltd. Appoints New Principal Accounting Officer
Roivant Sciences Ltd. announces the resignation of Rakhi Kumar from her role as Principal Accounting Officer, effective February 20, 2025. Jennifer Humes has been appointed as the new Principal Accounting Officer and Chief Accounting Officer of Roivant Sciences, Inc. The new compensation package for Ms. Humes includes an annual base salary of $380,000, a sign-on bonus of $261,500, a target annual cash bonus of $190,000, restricted stock units valued at approximately $1,200,000, and stock options valued at approximately $800,000.
- Filer
- Roivant Sciences Ltd ROIV · NASDAQ
- Filed
- Accession
- 0001140361-25-005445
- CIK
- 0001635088
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Financial Statements and Exhibits
Market reaction
Close before filing
$10.72
Next session
-1.9%
Since filing
+223.1%
Latest close
$34.64
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ROIV reporting the same item, with the next session's move:
About Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company focused on developing and commercializing innovative therapies through a unique model that emphasizes rapid and efficient drug delivery. As a platform company, Roivant Sciences incubates subsidiaries known as 'Vants,' each concentrating on a specific therapeutic area. This model allows Roivant to prioritize development of pharmaceuticals in critical areas, including neurology, oncology, immunology, and others. Roivant’s approach facilitates agility in drug development, enabling each Vant to operate semi-autonomously to accelerate research and commercialization efforts. By leveraging technology and data analytics, Roivant enhances drug discovery processes and optimizes clinical trials. In the pharmaceutical industry, Roivant Sciences represents a forward-thinking entity that addresses unmet medical needs by transforming the traditional paradigms of drug development. Its initiatives have substantial implications for healthcare, potentially altering treatment landscapes and improving patient outcomes globally. Founded in 2014 and headquartered in New York City, Roivant is a notable example of innovation-driven pharmaceutical enterprise in the financial market.
Never miss another ROIV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.